IBM Watson has been all over the place in the past couple of years, reaching into many different health fields, from cancer research to care delivery, and has reached few goals. The company's IP filings demonstrate this, with filings in many different AI biotech sector categories over the last two years.
Paul Roma recently took over the Watson Health division, having previously been CEO of Ciox Heath, a clinical data company. He has announced that his strategy for Watson is focus, the group is ending bids for new clients and doubling down on clinical development. Looking forward, this means that IP filings may also become more consistent - both for IBM itself, but also for companies of all sizes which it is currently partnering with.
